Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

17.14 -0.08 (-0.46%)
Streaming Delayed Price Updated: 2:23 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗
Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets. 
Via The Motley Fool
Topics Regulatory Compliance
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗
Via Stocktwits
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 ↗
Via Stocktwits
News headline image
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care. 
Via The Motley Fool
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗
Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts. 
Via Stocktwits
News headline image
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗
The investor day update comes after a stock collapse last year following mixed Phase 3 VELA trial results that raised concerns about approval risk. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment was stabilizing for SPY and QQQ. 
Via Stocktwits
Topics ETFs Economy Lawsuit
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day. 
Via Stocktwits
News headline image
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗
Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 
Via Stocktwits
Topics Intellectual Property
News headline image
BioTech Breakout: MoonLake Up 30% On FDA Wins ↗
Via MarketBeat
News headline image
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗
The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials. 
Via Stocktwits
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its... 
Via MarketMinute
Topics Intellectual Property
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder. 
Via Stocktwits
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
The Best AI for Picking Stocks, Ranked by Performance ↗
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Which stocks have an unusual volume on Monday? ↗
Volume analysis on 2025-10-06: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗
 
Via Benzinga
News headline image
Unusual volume stocks are being observed in Friday's session. ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
Unusual volume stocks are being observed in Thursday's session. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside ↗
Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.